Advisors Asset Management Inc. Grows Holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Advisors Asset Management Inc. boosted its holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) by 41.6% in the 2nd quarter, Holdings Channel reports. The firm owned 2,767 shares of the biopharmaceutical company’s stock after purchasing an additional 813 shares during the period. Advisors Asset Management Inc.’s holdings in Horizon Therapeutics Public were worth $221,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Samalin Investment Counsel LLC purchased a new stake in Horizon Therapeutics Public in the 1st quarter valued at $41,000. Tcwp LLC purchased a new stake in Horizon Therapeutics Public in the 1st quarter valued at $41,000. Parallel Advisors LLC raised its position in Horizon Therapeutics Public by 65.9% during the 1st quarter. Parallel Advisors LLC now owns 408 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 162 shares during the last quarter. MUFG Americas Holdings Corp purchased a new position in Horizon Therapeutics Public during the 1st quarter worth $48,000. Finally, Steward Financial Group LLC purchased a new position in Horizon Therapeutics Public during the 2nd quarter worth $41,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. UBS Group downgraded shares of Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $137.00 to $71.00 in a research report on Thursday, August 4th. StockNews.com upgraded shares of Horizon Therapeutics Public from a “hold” rating to a “buy” rating in a research report on Thursday, November 3rd. BMO Capital Markets cut their price objective on shares of Horizon Therapeutics Public from $145.00 to $117.00 and set an “outperform” rating for the company in a research report on Thursday, August 4th. HC Wainwright began coverage on shares of Horizon Therapeutics Public in a research note on Tuesday, November 1st. They set a “neutral” rating and a $74.00 price target on the stock. Finally, TheStreet cut shares of Horizon Therapeutics Public from a “b” rating to a “c+” rating in a research note on Tuesday, August 16th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $105.00.

Horizon Therapeutics Public Price Performance

Shares of NASDAQ HZNP opened at $76.26 on Monday. The stock has a market cap of $17.28 billion, a price-to-earnings ratio of 31.25, a PEG ratio of 1.52 and a beta of 1.09. Horizon Therapeutics Public Limited has a 52 week low of $57.84 and a 52 week high of $117.49. The company’s 50-day moving average price is $66.78 and its 200 day moving average price is $74.47. The company has a current ratio of 3.96, a quick ratio of 3.74 and a debt-to-equity ratio of 0.51.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Recommended Stories

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.